NAHA, a novel hydroxamic acid-derivative, inhibits growth and angiogenesis of breast cancer in vitro and in vivo

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Jiang, Jiahua ^a   Thyagarajan Sahu, Anita ^a   Krchňák, Viktor ^b   Jedinak, Andrej ^a   Sandusky, George E ^c   Sliva, Daniel ^a,c  

^a METHODIST RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [BENZYL (2 NITROBENZENESULFONYL)AMINO] N HYDROXY 3 METHYL N PROPYLBUTYRAMIDE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANAPC4 PROTEIN; ANAPC5 PROTEIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CD31 ANTIGEN; CDC25C PROTEIN; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 20; CKS1B PROTEIN; CKS2 PROTEIN; CULIN 1; CYCLIN B1; CYCLIN DEPENDENT KINASE 2; CYCLIN H; CYCLINE; HYDROXAMIC ACID DERIVATIVE; KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 2; SURVIVIN; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN; 2 (BENZYL (2 NITROBENZENESULFONYL)AMINO) N HYDROXY 3 METHYL N PROPYLBUTYRAMIDE; 2-(BENZYL-(2-NITROBENZENESULFONYL)AMINO)-N-HYDROXY-3-METHYL-N-PROPYLBUTYRAMIDE; AMIDE; BUTYRAMIDE; DRUG DERIVATIVE; HYDROXAMIC ACID; VALINE; VASCULOTROPIN A;

ANAPC4 GENE; ANAPC5 GENE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CAPILLARY MORPHOGENESIS; CDC20 GENE; CDC25C GENE; CDK2 GENE; CELL ADHESION; CELL ASSAY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CKS1B GENE; CKS2 GENE; COLONY FORMATION; CONTROLLED STUDY; CULIN 1 GENE; CYCLIN B1 GENE; CYCLIN H GENE; DNA MICROARRAY; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG STRUCTURE; E2F1 GENE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; FEMALE; GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KI 67 GENE; MCM2 GENE; METASTASIS POTENTIAL; MITOSIS INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; SOFT AGAR ASSAY; SURVIVIN GENE; TFDP1 GENE; TUMOR VOLUME; TUMOR WEIGHT; TUMOR XENOGRAFT; VASCULAR ENDOTHELIAL CELL; WEIGHT; WESTERN BLOTTING; ANIMAL; BREAST TUMOR; CANCER INVASION; CANCER TRANSPLANTATION; CHEMICAL MODEL; CHEMISTRY; DRUG SCREENING; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

AMIDES; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, NUDE; MODELS, CHEMICAL; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; VALINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859021896     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034283     Document Type: Article

References (36)

1. Levin JI, (2004) The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE. Curr Top Med Chem 4: 1289-1310.
2. Coussens LM, Fingleton B, Matrisian LM, (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392.
3. Peterson JT, (2006) The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res 69: 677-687.
4. Parvathy S, Hussain I, Karran EH, Turner AJ, Hooper NM, (1998) The amyloid precursor protein (APP) and the angiotensin converting enzyme (ACE) secretase are inhibited by hydroxamic acid-based inhibitors. Biochem Soc Trans 26: S242.
5. Barta TE, Becker DP, Bedell LJ, De Crescenzo GA, McDonald JJ, et al. (2001) Selective, orally active MMP inhibitors with an aryl backbone. Bioorg Med Chem Lett 11: 2481-2483.
6. Almstead NG, Bradley RS, Pikul S, De B, Natchus MG, et al. (1999) Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. J Med Chem 42: 4547-4562.
7. MacPherson LJ, Bayburt EK, Capparelli MP, Carroll BJ, Goldstein R, et al. (1997) Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem 40: 2525-2532.
8. Santos MA, Marques S, Gil M, Tegoni M, Scozzafava A, et al. (2003) Protease inhibitors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating succinyl hydroxamate and iminodiacetic acid hydroxamate moieties. J Enzyme Inhib Med Chem 18: 233-242.
9. Stanger KJ, Sliva D, Jiang J, Krchnak V, (2006) Synthesis and screening of N-alkyl hydroxamates for inhibition of cancer cell proliferation. Comb Chem High Throughput Screen 9: 651-661.
10. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
11. Pasqualini JR, (2004) The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta 1654: 123-143.
12. Price JT, Thompson EW, (2002) Mechanisms of tumour invasion and metastasis: emerging targets for therapy. Expert Opin Ther Targets 6: 217-233.
13. Price JT, Bonovich MT, Kohn EC, (1997) The biochemistry of cancer dissemination. Crit Rev Biochem Mol Biol 32: 175-253.
14. Folkman J, (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
15. Wang LH, (2004) Molecular signaling regulating anchorage-independent growth of cancer cells. Mt Sinai J Med 71: 361-367.
16. Wong NC, Mueller BM, Barbas CF, Ruminski P, Quaranta V, et al. (1998) Alphav integrins mediate adhesion and migration of breast carcinoma cell lines. Clin Exp Metastasis 16: 50-61.
17. Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D, (2004) Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-kappaB signaling. Nutr Cancer 49: 209-216.
18. Sliva D, Jedinak A, Kawasaki J, Harvey K, Slivova V, (2008) Phellinus linteus suppresses growth, angiogenesis and invasive behaviour of breast cancer cells through the inhibition of AKT signalling. Brit J Cancer 98: 1348-1356.
19. Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Nakamura Y, et al. (2008) CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27: 1562-1571.
20. Wasch R, Engelbert D, (2005) Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene 24 (1): 1-10.
21. Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, et al. (2006) Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 12: 405-410.
22. Jiang J, Jedinak A, Sliva D, (2011) Ganodermanontriol (GDNT) exerts its effect on growth and invasiveness of breast cancer cells through the down-regulation of CDC20 and uPA. Biochem Biophys Res Commun 415: 325-329.
23. Andreasen PA, Kjoller L, Christensen L, Duffy MJ, (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22.
24. Chapman HA, Riese RJ, Shi GP, (1997) Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 59: 63-88.
25. Yu AE, Hewitt RE, Connor EW, Stetler-Stevenson WG, (1997) Matrix metalloproteinases. Novel targets for directed cancer therapy. Drugs Aging 11 (3): 229-244.
26. Amir S, Margaryan NV, Odero-Marah V, Khalkhali-Ellis Z, Hendrix MJ, (2005) Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells. Cancer Biol Ther 4: 400-406.
27. Pakneshan P, Szyf M, Rabbani SA, (2005) Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells. Carcinogenesis 26: 557-564.
28. Slivova V, Zaloga G, DeMichele SJ, Mukerji P, Huang YS, et al. (2005) Green tea polyphenols modulate secretion of urokinase plasminogen activator (uPA) and inhibit invasive behavior of breast cancer cells. Nutr Cancer 52: 66-73.
29. Blasi F, Carmeliet P, (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3: 932-943.
30. Fukumoto S, Morifuji M, Katakura Y, Ohishi M, Nakamura S, (2005) Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis 22: 31-38.
31. Jang YJ, Kim DS, Jeon OH, Kim DS, (2007) Saxatilin suppresses tumor-induced angiogenesis by regulating VEGF expression in NCI-H460 human lung cancer cells. J Biochem Mol Biol 40: 439-443.
32. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH, (2007) Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 67: 3310-3319.
33. Stanley G, Harvey K, Slivova V, Jiang J, Sliva D, (2005) Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells. Biochem Biophys Res Commun 330: 46-52.
34. Slivova V, Jiang J, Sliva D, (2004) Ganoderma lucidum inhibits invasiveness of breast cancer cells. J Cancer Integr Med 2: 25-30.
35. Sliva D, Labarrere C, Slivova V, Sedlak M, Lloyd FP Jr, et al. (2002) Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. Biochem Biophys Res Commun 298: 603-612.
36. Lloyd FP Jr, Slivova V, Valachovicova T, Sliva D, (2003) Aspirin inhibits highly invasive prostate cancer cells. Int J Oncol 23: 1277-1283.